Get Live Data

Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Glaxosmithkline Share Price
  4. Glaxosmithkline Share Regulatory News
  5. Block Listing Application

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1950.00    0.00 (0.00%)
Bid:
1887.50
Ask:
2150.00
Spread: 262.50 (13.907%)
Market Cap: £78.13b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Block Listing Application

11 Dec 2025 09:00

RNS Number : 0709L
GSK PLC
11 December 2025
 

 

Issued: 11 December 2025, London UK

 

Block Listing Application

 

 

Application has been made to the Financial Conduct Authority and the London Stock Exchange plc for a total of 250,000 Ordinary Shares of 31¼p each ('Shares') to be admitted to the Official List.

 

The Shares are being reserved under a block listing and will be issued under the GlaxoSmithKline plc Share Save Plan 2022.

 

When issued, the Shares will rank pari passu with the existing Ordinary Shares of 31¼p each.

 

Admission is expected to be effective on 12 December 2025.

 

 

 

 

V A Whyte

Company Secretary

 

11 December 2025

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ALSPKKBDABDDFBD
141516171819202122
Date   Source Headline
22nd Sep 20227:00 amRNSGSK and Spero Therapeutics licence for tebipenem
21st Sep 202211:22 amRNSDirector/PDMR Shareholding
13th Sep 20229:11 amRNSDirector/PDMR Shareholding
9th Sep 20229:11 amRNSPublication of Base Prospectus
8th Sep 202212:58 pmRNSDirector/PDMR Shareholding
6th Sep 20221:00 pmRNSGSK provides update on FDA review of daprodustat
1st Sep 202211:48 amRNSTotal Voting Rights
24th Aug 20227:00 amRNSGSK Board changes
22nd Aug 20224:53 pmRNSDirector/PDMR Shareholding
17th Aug 20227:00 amRNSFDA New Drug Application File Acceptance for MMB
17th Aug 20227:00 amRNSStatement: Zantac (ranitidine) litigation update
16th Aug 20227:06 amRNSGSK completes acquisition of Affinivax, Inc.
12th Aug 20227:00 amRNSStatement: Zantac (ranitidine) litigation
11th Aug 202211:51 amRNSDirector/PDMR Shareholding
10th Aug 20224:57 pmRNSDirector/PDMR Shareholding
1st Aug 20226:10 pmRNSTotal Voting Rights
1st Aug 20221:43 pmRNSDirector/PDMR Shareholding
29th Jul 20222:00 pmRNSDirector/PDMR Shareholding
29th Jul 202210:00 amRNSGSK Board change
28th Jul 20221:01 pmRNSDirector/PDMR Shareholding
27th Jul 20227:00 amRNS2nd Quarter Results
26th Jul 20225:35 pmRNSHolding(s) in Company
22nd Jul 20224:45 pmRNSHolding(s) in Company
22nd Jul 20224:17 pmRNSBoard and Committee Changes
19th Jul 20227:00 amRNSCompletion of GSK Share Consolidation
18th Jul 20226:00 pmRNSHolding(s) in Company
18th Jul 20227:00 amRNSHaleon demerger completion and share consolidation
12th Jul 20229:48 amRNSDirector/PDMR Shareholding
11th Jul 20225:30 pmRNSGSK
8th Jul 20226:04 pmRNSDirector/PDMR Shareholding
8th Jul 20225:30 pmRNSDirector/PDMR Shareholding
8th Jul 20223:53 pmRNSDirector/PDMR Shareholding
8th Jul 20223:33 pmRNSDirector/PDMR Shareholding
8th Jul 20223:10 pmRNSDirector/PDMR Shareholding
6th Jul 20224:30 pmRNSResult of General Meeting
6th Jul 202210:11 amRNSDirector/PDMR Shareholding
5th Jul 202212:43 pmRNSGSK disclose discontinued operations from Q2 2022
5th Jul 20229:45 amRNSDirector/PDMR Shareholding
5th Jul 20229:30 amRNSDirector/PDMR Shareholding
1st Jul 20223:27 pmRNSTotal Voting Rights
1st Jul 20222:45 pmRNSGSK completes acquisition of Sierra Oncology
28th Jun 20225:56 pmRNSDirector/PDMR Shareholding
28th Jun 20227:00 amRNSGSK files Shingrix 18+ at risk indication in Japan
27th Jun 20224:08 pmRNSDirector/PDMR Shareholding
24th Jun 20223:44 pmRNSDirector/PDMR Shareholding
16th Jun 202210:58 amRNSDirector/PDMR Shareholding
10th Jun 20227:00 amRNSPositive phase III data for GSK’s RSV OA vaccine
9th Jun 20224:28 pmRNSDirector/PDMR Shareholding
7th Jun 20225:17 pmRNSDirector/PDMR Shareholding
7th Jun 202212:00 pmEQSHardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
141516171819202122

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
DARK
Darktrace
LSE
0.00%
PIC
PIC.L
LSE
0.00%
EXI
EXI.L
LSE
0.00%
BCI
BCI.L
LSE
0.00%
ABAL
ABAL.L
LSE
0.00%
Trending
AVCT
Avacta Group
LSE
0.00%
RRR
Red Rock Resources
LSE
0.00%
TRP
Tower Resources
LSE
0.00%
EZJ
easyJet
LSE
0.00%
MATD
Petro Matad
LSE
0.00%